On March 28, 2017 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported it will present preclinical results from recent studies describing the latest developments of its gene delivery platform, at a poster session at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, in Washington, D.C., on April 1- 5, 2017 (Press release, OncoSec Medical, MAR 28, 2017, View Source [SID1234518300]). Schedule your 30 min Free 1stOncology Demo! Details of the poster abstract are as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Title: Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response (Abstract ID #: 1614)
Session Title: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017 / 8:00 a.m. – 12:00 p.m. EDT
Location: Convention Center, Halls A – C, Poster Section 26
Further details on the poster presentation will be provided in upcoming Company communications. For more information about this conference, please visit: www.aacr.org.